Myriad Genetics (MYGN)
(Real Time Quote from BATS)
$26.48 USD
-1.12 (-4.06%)
Updated Aug 2, 2024 12:56 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
MYGN 26.48 -1.12(-4.06%)
Will MYGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYGN
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
INCY or MYGN: Which Is the Better Value Stock Right Now?
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
Other News for MYGN
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
Myriad Genetics completes sale of EndoPredict Business to Eurobio Scientific
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
Myriad Genetics appoints Jennifer Fox as CLO
What's Driving NeoGenomics Inc's Surprising 23% Stock Rally?